Alnylam Pharmaceuticals | ALNY - Ebitda


Alnylam Pharmaceuticals reported $360.27M in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
Agios Pharmaceuticals USD -109.2M 540K Jun/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Amgen USD 5.8B 1.25B Sep/2026
Arrowhead Research USD -147.68M 40.33M Jun/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -95.22M 9.99M Sep/2026
Moderna USD -687M 571M Jun/2026
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
Novartis USD 5.36B 45M Sep/2026
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Sanofi EUR 6.66B 4.99B Sep/2026
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
Takeda JPY 369.75B 5.29B Sep/2026
Tectonic Therapeutic USD -21.18M 365K Dec/2025
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Vertex Pharmaceuticals USD 888.6M 436.6M Sep/2026
Xencor USD 25.1M 59.73M Sep/2026